5G

Biogen Presents Data from Phase 1b Study of Investigational Alzheimer s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer s Disease Meeting

Chief Editor December 9, 2016 0 12 sec read
Biogen (NASDAQ: BIIB) announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimer’s disease (AD), today at the 9 th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego.

Posted: 2016-12-09 00:41:00

Read all

Chief Editor

View More Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Brazil

Download the full report: https://www.reportbuyer.com/product/4710247/ The country’s telecom infrastructure will be significantly augmented during the next two years as additional submarine cables become ready for […]

February 22, 2017 0 12 sec read

Mukesh Ambani | RIL AGM: RIL AGM: Will Mukesh Ambani surprise investors today?

NEW DELHI: Given Mukesh Ambani’s history of making key announcements at ’ annual general meeting (AGM), investors are wondering if India’s largest company by market […]

August 29, 2022 0 38 sec read

BTI Systems to Present at Carrier Ethernet APAC / Peter Green to Explore the Maturity of Carrier Ethernet Technologies; Company Shortlisted as a Finalist in Three Categories of Carrier Ethernet APAC Awards Program

OTTAWA and BOSTON, MA — (Marketwire) — 11/27/12 — BTI Systems, the software and networking leader empowering content and service providers to capitalize on trends […]

November 28, 2012 0 9 sec read

Boehner endorses Kasich days before Ohio primary

WEST CHESTER, Ohio — Republicans in Butler County honored former House Speaker John Boehner three days before residents across Ohio’s 8th District will vote on […]

March 13, 2016 0 12 sec read